Entera Bio, Opko Health provide update on PK/PD results of GLP-1/Glucagon

Entera Bio (ENTX) and OPKO Health (OPK) announced topline pharmacokinetic/pharmacodynamic, PK/PD, results from their ongoing collaborative research combining a proprietary long-acting oxyntomodulin analog developed by OPKO and Entera’s proprietary N-Tab technology. The program is focused on developing the first oral dual agonist GLP-1/glucagon peptide as a potential once-daily treatment for patients with obesity, metabolic and fibrotic disorders. OXM is a naturally occurring peptide hormone found in the small intestine that acts to suppress appetite and induce weight loss. Entera and OPKO have completed in vivo proof-of-concept PK/PD studies in rodent and pig models. The studies’ objectives were met with oral OXM exhibiting significant systemic exposure following a single dose in both models. Furthermore, a favorable PK profile and bioavailability were shown with oral OXM. In the pig model, oral OXM achieved high plasma concentrations with prolonged systemic exposure, which is consistent with the reported half-life for semaglutide, the only approved oral GLP-1 analog.